SCHEMBL23950967

SCHEMBL23950967

CCOC(=O)Cn1nc(C(C)C)n2nc(C3CC3)c(NOC)c2c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.34
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
NLRP3 Q96P20 1/20 0.33
TOP2A P11388 1/20 0.31
TOP2B Q02880 1/20 0.31
MAPK1 P28482 1/20 0.31
NPC1 O15118 1/20 0.31
HTT P42858 1/20 0.31
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25752450 0.90 KDM4E (0.38) CYP2C19CYP1A2CYP3A4CYP2C9L3MBTL1
SCHEMBL23950797 0.84 TOP2A (0.38) CYP2C19CYP1A2CYP3A4CYP2C9L3MBTL1
SCHEMBL25247216 0.81 HTT (0.35) CYP2C19CYP1A2CYP3A4CYP2C9L3MBTL1
SCHEMBL23950971 0.80 GAA (0.33) CYP2C19CYP1A2CYP3A4CYP2C9L3MBTL1
SCHEMBL23950194 0.77 NLRP3 (0.37) NLRP3
SCHEMBL25752270 0.74 GAA (0.35) CYP2C19CYP1A2CYP3A4CYP2C9L3MBTL1
SCHEMBL25754220 0.73 NLRP3 (0.56) NLRP3
SCHEMBL23950211 0.73 NLRP3 (0.55) CYP2C19CYP1A2CYP3A4CYP2C9L3MBTL1
SCHEMBL23950186 0.71 NLRP3 (0.36) NLRP3TOP2ATOP2B
SCHEMBL25753005 0.69 NLRP3 (0.51) KMT2ANLRP3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021209552-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2021-10-21 WO disclosed